CRISPR Therapeutics AG — Director's Dealing 2016

Oct 20, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2016-10-18

Reporting Person: Novak Rodger (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-10-18	Stock Option (Right to Buy)	$14.00	A	200000	Acquired	2026-10-18	Common Shares (200000)	Direct

Footnotes

F1: This option was granted on October 18, 2016 with respect to 200,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.